Medpace Holdings Inc.
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$13.14B
Cash Runway
50.0 mo
Lead Asset
—
Next Catalyst
—
Go deeper on Medpace Holdings Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on MEDP — live, with citations.
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
50.0 months
D/E 2.56 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Key Financialsas of March 31, 2026
Cash
$652.7M
Quarterly Burn
$47.9M
Revenue
$706.6M
Free Cash Flow
$145.0M
Total Liabilities
$1.53B
Shareholders Equity
$598.3M
Current Ratio
0.85
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Commercialization & Governance
Commercialization
- Partnerships
- Partners with imaging experts from major academic and clinical institutions for image reading; uses a third-party customer relationship management tool to house sales and marketing data.
- Launch Markets
- United StatesEuropean UnionUnited KingdomCanadaAsiaLatin America
- Commercial Strategy
- Integrated sales and marketing team using a consultative, strategic sales approach with medical and scientific experts engaged from the start; customer segmentation model targeting addressable market and matching customer characteristics with therapeutic fit; focus on full-service outsourcing, structured account evaluation, and alignment of sales and marketing supported by third-party CRM analytics; marketing supports brand awareness, conferences and lead generation.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
724
Total value held
$10.95B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,470,440 | $1.19B |
| vanguard capital management llc | 2,022,142 | $971.0M |
| aqr capital management llc | 1,353,837 | $633.6M |
| vanguard portfolio management llc | 1,121,689 | $538.6M |
| wasatch advisors lp | 773,931 | $371.6M |
| geode capital management, llc | 745,106 | $357.8M |
| state street corp | 682,229 | $327.6M |
| renaissance technologies llc | 504,668 | $242.3M |
| mawer investment management ltd. | 446,104 | $214.2M |
| d. e. shaw & co., inc. | 432,602 | $207.7M |
Showing top 10 of 724 institutional holders of Medpace Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
Who is the CEO of Medpace Holdings Inc.?
Dr. August James Troendle M.D. is the chief executive officer of Medpace Holdings Inc. (MEDP).
Where is Medpace Holdings Inc. headquartered?
Medpace Holdings Inc. (MEDP) is headquartered in Cincinnati, OH, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Medpace Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.